Navigation Links
MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million
Date:1/30/2008

ization of anti-infective drug products that fulfill substantial unmet medical needs in the treatment of infectious disease. The Company is developing anti-infective drugs based on its novel biological finding that bacteria exposed to antibiotics in front- loaded staccato bursts, or "pulses," are killed more efficiently and effectively than those under standard treatment regimens. Based on this finding, MiddleBrook has developed a proprietary, once-a-day pulsatile delivery technology called PULSYS(TM). The Company currently markets the Keflex(R) brand of cephalexin and has received regulatory approval for MOXATAG(TM) -- the first and only once-daily amoxicillin product approved for marketing in the U.S. For more on MiddleBrook, please visit http://www.middlebrookpharma.com.

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on MiddleBrook's current expectations and assumptions. These statements are not guarantees of future performance and are subject to a number of risks and uncertainties that would cause actual results to differ materially from those anticipated. The words, "believe," "expect," "intend," "anticipate," and variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward- looking. Statements in this announcement that are forward-looking include, but are not limited to, statements about the Company's future development plans, clinical trials, potential commercial success, and any financial forecasts included in this announcement.

The actual results realized by MiddleBrook could differ materially from these forward-looking statements, depending in particular upon the risks and uncertainties described in the Company's fil
'/>"/>

SOURCE MiddleBrook Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sagent Pharmaceuticals, Inc. to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
2. Access Pharmaceuticals Announces $2.7 Million New Equity
3. Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award
4. Alexion Pharmaceuticals Invites You to Participate in its Fourth Quarter and Full Year 2007 Results Conference Call and Web Cast
5. Cylene Pharmaceuticals Appoints Kenna Anderes, Ph.D. as Vice President of Cancer Biology
6. Onyx Pharmaceuticals to Present at Wachovia Healthcare Conference
7. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
8. Angiotech Pharmaceuticals, Inc. - Notice of Conference Call and Webcast
9. VIA Pharmaceuticals Names Rebecca Taub Senior Vice President of Research and Development
10. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
11. Cerimon Pharmaceuticals Names Matthew J. Meyer its General Counsel and Vice President of Business Development and Licensing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 This webinar ... on nonclinical and clinical safety assessment in biosimilars. ... guide a path for biosimilar drug development, however ... of biosimilarity with regards to quality, safety and ... of biosimilar drug development and registration, development strategies ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 ... an enhancement to its Online Web Portal for Life ... now have the ability to specify the subject matter ... nearly 50 life science sub-domains. This will help reduce ... and scientific fields, and decrease the likelihood of error. ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 ... – 11 p.m. , Location: Warrington Country Club, 1360 ... Hepatitis B Foundation, the only national nonprofit organization solely ... improving the quality of life for those affected worldwide, ... 11 at Warrington Country Club in Warrington, Pa. ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... initiated coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua ... and marketing proprietary products to serve the wound ... , In late 2012, Alliqua was restructured ... launched the company’s new strategy to become a ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... Scheduled for Thursday, May 7, 2009 at 5:30 p.m. Eastern ... ALXA ) announced today that it will release ... on Thursday, May 7, 2009, following the close of the ... conference call to discuss the financial results and other clinical ...
... at 5:00 p.m. ET (22:00 CET)NOVATO, Calif., April 30 , ... ... BioMarin Revenue $74.0 ... $71.9 ...
... Bio, Maxis IT and Rescentris recognized for their innovation across the ... ... Boston (PRWEB) April 30, 2009 -- CHI,s Bio-IT World Conference ... named Best of Show Awards winners at a ceremony held Tuesday, ...
Cached Biology Technology:Alexza to Announce 2009 First Quarter Financial Results and Update Its Clinical Pipeline Status on Thursday, May 7, 2009 2Alexza to Announce 2009 First Quarter Financial Results and Update Its Clinical Pipeline Status on Thursday, May 7, 2009 3BioMarin Announces First Quarter 2009 Financial Results 2BioMarin Announces First Quarter 2009 Financial Results 3BioMarin Announces First Quarter 2009 Financial Results 4BioMarin Announces First Quarter 2009 Financial Results 5BioMarin Announces First Quarter 2009 Financial Results 6BioMarin Announces First Quarter 2009 Financial Results 7BioMarin Announces First Quarter 2009 Financial Results 8BioMarin Announces First Quarter 2009 Financial Results 9BioMarin Announces First Quarter 2009 Financial Results 10BioMarin Announces First Quarter 2009 Financial Results 11BioMarin Announces First Quarter 2009 Financial Results 12BioMarin Announces First Quarter 2009 Financial Results 13BioMarin Announces First Quarter 2009 Financial Results 14BioMarin Announces First Quarter 2009 Financial Results 15BioMarin Announces First Quarter 2009 Financial Results 16Best of Show Awards Winners Named at Bio-IT World Conference & Expo 2Best of Show Awards Winners Named at Bio-IT World Conference & Expo 3Best of Show Awards Winners Named at Bio-IT World Conference & Expo 4Best of Show Awards Winners Named at Bio-IT World Conference & Expo 5
(Date:4/15/2014)... have found a less invasive way to extract ... study how the mouth,s natural defenses ward off ... immune cells (white blood cells known as "leukocytes") ... mouthor reject foreign tissues, such as in failed ... and preventing such health issues as oral cancers, ...
(Date:4/15/2014)... in the world for which no pharmaceutical treatment exists. ... by mosquitoes in the tropics, as well as a ... and is easily spread by the hands and can ... , Researchers at Aalto University and the University of ... prevent the spread of one type of virus into ...
(Date:4/15/2014)... April 15, 2014 New research, partially funded by ... Federation, shows that consumers can improve their diets simply ... their daily meals. , In a ... and Nutrition Sciences , lead author Theresa Nicklas, DrPH, ... and Nutrition Examination Survey datasets from 2005-2010 and evaluated ...
Breaking Biology News(10 mins):New method isolates immune cells for researchers to study how they ward off oral diseases 2Nanocrystalline cellulose modified into an efficient viral inhibitor 2Eating rice boosts diet quality, reduces body weight and improves markers for health 2Eating rice boosts diet quality, reduces body weight and improves markers for health 3
... added to the threatened species list nearly three years ago ... a warming climate. , But it appears the Arctic icons ... study published in this week,s issue of the journal ... no "tipping point" that would result in unstoppable loss of ...
... appearing in the January Journal of Lipid Research ... in any significant amount in multiple sclerosis patients, contradicting ... cholesterol metabolites were associated with MS and could be ... are somewhat controversial in science; while some laboratory experiments ...
... The virus that causes AIDS is chameleon-like in its ... mutates into forms that can evade even the best ... change as they reproduce is key to developing better ... Journal of Biological Chemistry and Nature Structural & ...
Cached Biology News:Polar bears: On thin ice? Extinction can be averted, scientists say 2Polar bears: On thin ice? Extinction can be averted, scientists say 3Link between cholesterol compound and multiple sclerosis unlikely, researchers say 2New discoveries make it harder for HIV to hide from drugs 2
Mouse polyclonal antibody raised against a partial recombinant WRB. NCBI Entrez Gene ID = 7485...
...
Mouse monoclonal to Casein Kinase 2 beta ( Abpromise for all tested applications). entrezGeneID: 1460 SwissProtID: P13862...
Mouse monoclonal antibody raised against a partial recombinant FAAH. NCBI Entrez Gene ID = FAAH...
Biology Products: